An interventional study of Kava (Piper methysticum) extract in Sleep, sponsored by Thorne HealthTech, Inc. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-13.
Sponsored by Thorne HealthTech, Inc · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This research study is being done to better understand the effects of kava supplementation on sleep quality and salivary cortisol in the context of the acute physical and psychological stress of military special forces preparation training. Kava is a botanical dietary supplement derived from the plant Piper methysticum. Cortisol is a hormone associated with stress.
Acute physical and behavioral stress can interfere with sleep quality and cause cortisol to increase. This can have a negative impact on quality of life and the ability to perform optimally.
Kava, derived from the rootstumps of the Piper methysticum plant, has been utilized traditionally, socially, and for its calmative properties by the peoples of Oceania for millennia. Kava has been available as a dietary supplement for decades.
Participants in this placebo-controlled cross-over study will be enrolled concurrently with a special operations prep class during which they will be experiencing significant physical and mental stressors. Participants will be divided into two arms - one taking kava and the other taking placebo for the first two-week phase of the study. Following a washout and cross-over, participants will switch what they are taking for the second two-week phase.
Thorne HealthTech, Inc is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomly allocated to Cohort 1 for Phase 1 will begin the study taking the active ingredient and will cross-over to taking placebo in Phase 2 of the study after a washout period.
Dietary Supplement: Kava (Piper methysticum) extract
Participants randomly allocated to Cohort 2 for Phase 1 will begin the study taking the placebo and will cross-over to taking the active ingredient in Phase 2 of the study after a washout period.
Dietary Supplement: Kava (Piper methysticum) extract
Drug page: Piper methysticum rootStudies of Piper methysticum rootPiper methysticum root pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
Change in Salivary Cortisol - Phase 1
Diurnal salivary samples will be collected and tested for cortisol levels \[ng/ml\].
Time frame: Day 1 and 15
Change in Salivary Cortisol - Phase 2
Diurnal salivary samples will be collected and tested for cortisol levels \[ng/ml\].
Time frame: Day 1 and 15
Change in Sleep Latency, Duration, and Quality - Phase 1
Data from the Restorative Sleep Questionnaire-Weekly (RSQ-W) \[Total score 0-100; higher indicates better restorative sleep\] plus other selected sleep questions will be combined to assess participant sleep during the study.
Time frame: Day 1, 8, and 15
Change in Sleep Latency, Duration, and Quality - Phase 2
Data from the Restorative Sleep Questionnaire-Weekly (RSQ-W) \[Total score 0-100; higher indicates better restorative sleep\] plus other selected sleep questions will be combined to assess participant sleep during the study.
Time frame: Day 1, 8, and 15
Change in General Mood - Phase 1
Data from the Depression, Anxiety, and Stress Scale-21 (DASS-21) \[Total score 0-63; higher is more distressed\] will be used non-diagnostically to generate comparative scores which will be analyzed against the cortisol findings to assist in the interpretation of the kava-related outcomes.
Time frame: Day 1, 8, and 15
Change in General Mood - Phase 2
Data from the Depression, Anxiety, and Stress Scale-21 (DASS-21) \[Total score 0-63; higher is more distressed\] will be used non-diagnostically to generate comparative scores which will be analyzed against the cortisol findings to assist in the interpretation of the kava-related outcomes.
Time frame: Day 1, 8, and 15
Change in Motivation and Volition - Phase 1
Data from the Cravings for Rest and Volitional Energy Expenditure Scale (CRAVE) \[Total score 0-50; higher is more motivated\] will be used to assess participant motivation to perform in the context of the strenuous and demanding training schedule of this Prep Class.
Time frame: Day 1, 8, and 15
Change in Motivation and Volition - Phase 2
Data from the Cravings for Rest and Volitional Energy Expenditure Scale (CRAVE) \[Total score 0-50; higher is more motivated\] will be used to assess participant motivation to perform in the context of the strenuous and demanding training schedule of this Prep Class.
Time frame: Day 1, 8, and 15
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jul 2022, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piper methysticum root